Compare Quest Diagnostics Inc (DGX) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs VanEck Rare Earth/Strategic Metals — how do they compare? Quest Diagnostics Inc trades at $237.3 (market cap $26.21B), while VanEck Rare Earth/Strategic Metals trades at $77.2. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while VanEck Rare Earth/Strategic Metals pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| DGX | REMX | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | Sector/Thematic |
52-Week High | $238.50 | $109.53 |
52-Week Low | $173.49 | $56.60 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $77.24, down 1.54% with a bullish technical signal supported by moving averages. The ETF provides exposure to 38 global rare earth companies amid growing U.S. efforts to secure critical mineral supply chains. Recent news highlights Energy Fuels' Utah plant expansion and ongoing geopolitical focus on reducing China's rare earth dominance.
Outlook remains tied to U.S. industrial policy and rare earth demand, though high volatility (~50% annualized) and China concentration pose risks. Investor sentiment is mixed, balancing strategic importance against execution challenges in building domestic supply chains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
